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ABSTRACT
Gram-negative bacteria naturally produce and secrete nanosized outer membrane vesicles (OMVs). In
the human gastrointestinal tract, OMVs produced by commensal Gram-negative bacteria can mediate
interactions amongst host cells (including between epithelial cells and immune cells) and maintain
microbial homeostasis. This OMV-mediated pathway for host-microbe interactions could be exploited
to deliver biologically active proteins to the body. To test this we engineered the Gram-negative
bacterium Bacteroides thetaiotaomicron (Bt), a prominent member of the intestinal microbiota of all
animals, to incorporate bacteria-, virus- and human-derived proteins into its OMVs. We then used the
engineered Bt OMVs to deliver these proteins to the respiratory and gastrointestinal (GI)-tract to protect
against infection, tissue inflammation and injury. Our findings demonstrate the ability to express and
package both Salmonella enterica ser. Typhimurium-derived vaccine antigens and influenza A virus
(IAV)-derived vaccine antigens within or on the outer membrane of Bt OMVs. These antigens were in
a form capable of eliciting antigen-specific immune and antibody responses in both mucosal tissues
and systemically. Furthermore, immunisation with OMVs containing the core stalk region of the IAV
H5 hemagglutinin from an H5N1 strain induced heterotypic protection in mice to a 10-fold lethal dose
of an unrelated subtype (H1N1) of IAV. We also showed that OMVs could express the human
therapeutic protein, keratinocyte growth factor-2 (KGF-2), in a stable form that, when delivered orally,
reduced disease severity and promoted intestinal epithelial repair and recovery in animals administered
colitis-inducing dextran sodium sulfate. Collectively, our data demonstrates the utility and effectiveness
of using Bt OMVs as a mucosal biologics and drug delivery platform technology.
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Introduction
Described over 50 years ago by Bishop andWork (1965) as
“extracellular glycolipids” produced by Escherichia coli,
outer membrane vesicles (OMVs) are now considered to
be naturally produced and secreted by most Gram-
negative bacteria. Analyses of these 20–400 nm bilayered
lipid membrane spherical structures have shown that they
contain major components of the outer membrane such as
lipopolysaccharide (LPS) in addition to the periplasmic
contents of their ‘parent’ bacterium [1,2].
Historically, OMVs have been associated with patho-
genesis and the storage and transportation of virulence
factors produced by enteric Gram-negative pathogens
including Helicobacter pylori (VacA), Shigella dysenteriae
(Shiga toxin) and enterohemorrhagic Escherichia. coli
(ClyA) [3–5]. Recently, this paradigm for OMV function
has been questioned due to new evidence demonstrating
a non-pathogenic, mutualistic role for the OMVs pro-
duced by commensal gut bacteria. Members of the genus
Bacteroides exclusively package carbohydrate and protein
hydrolases in OMVs that perform a ‘social function’ by
providing substrates for utilization by other bacteria and
contributing tomicrobiota homeostasis [6,7].We [8,9] and
others [10] have extended these observations providing
evidence for a broader role of OMVs in gastrointestinal
(GI)-tract homeostasis and the ability of Bacteroides-
derived OMVs to influence host immune and epithelial
cell responses.
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OMVs can contain adhesins, sulfatases and proteases
which facilitate their interaction with host epithelial cells,
allowing them to enter these cells through numerous
routes, includingmicropinocytosis, lipid raft- and clathrin-
dependent endocytosis [11–13]. Bacillus fragilis OMVs
containing polysaccharide A are detected by dendritic
cells via Toll Like Receptor (TLR) 2 leading to enhanced
T regulatory cell activity and production of anti-
inflammatory cytokines (IL-10) that protect the host
from experimental colitis [10]. We have demonstrated
that OMVs produced by the human commensal bacterium
B. thetaiotaomicron (Bt) can activatemammalian intestinal
epithelial cell (IEC) intracellular Ca2+ signalling [8]. This
host cell Ca2+ signalling response was dependent on
Minpp, a novel constituent of these OMVs. Minpp is
a homologue of amammalian inositol phosphate polypho-
sphatase cell-signalling enzyme. Collectively, these findings
demonstrate a non-pathogenic and beneficial role for
OMVs produced by commensal Bacteroides species and
are consistent with the concept that packaging of bioactive
macromolecules in OMVs enables members of the intest-
inal microbiota to influence host cell physiology and estab-
lish bacteria-host mutualism [13].
It is feasible that this OMV-mediated pathway for host-
microbe interaction could be exploited and used to deliver
biologically active proteins to the body. Delivery to muco-
sal sites such as the GI- and respiratory tracts would be
particularly valuable as they are vulnerable to injury and
disease as a result of exposure to noxious environmental
chemicals and pathogens [13,14]. Indeed, OMVs from
Neisseria meningitides and Vibrio cholera have been incor-
porated into licensed vaccine formulations [15]; those
derived from N. meningitides have been successfully used
to immunise both children and adults and effectively con-
trol serogroup B meningococcal (MenB) disease outbreaks
[16,17]. However, there are several limitations to using
non-commensal, pathogen-derived OMVs as drug and
vaccine delivery systems, particularly: their potential for
unintended toxicity due to associated toxins; low expres-
sion levels of the heterologous antigens; variable efficacy
depending on source and formulation; and the need for
exogenous adjuvants in some applications. In principal,
these limitations could be overcome by bioengineering the
OMVs to improve their drug delivery capability [18].
Alternatively, non-pathogenic commensal bacteria could
be used as a source of OMVs to reduce toxicity and
improve safety.
To test this strategy we undertook a proof-of-
principle study to determine the suitability of using
OMVs produced by Bt to deliver bacteria-, virus- and
human-derived proteins to the respiratory and GI-tract
of mouse models (for respiratory influenza A virus
infection and acute intestinal colitis) to protect them
against infection, tissue inflammation and injury. Our
findings, presented here provide evidence for the utility
and effectiveness of using Bt OMVs as a mucosal bio-
logics and drug delivery platform technology.
Material and methods
Bacteria strains, media and culture
Bt and its derivative strains (Table 1) were grown
under anaerobic conditions at 37°C in an anaerobic
cabinet. Bacterial starter-cultures were grown overnight
in 20 ml “Brain Heart Infusion” (BHI) medium
(Oxoid) supplemented with 15 µM haemin (Sigma-
Aldrich) (BHIH). For OMV preparations, Bt cultures
were inoculated with 0.5 ml of the starter-culture in
a total volume of 500 ml BHI supplemented with
0.75 µM haemin. Cells were harvested after 16 h at an
approximate OD600 nm of 4.0, which corresponds to
early stationary phase. Antibiotic-resistance markers in
Bt were selected using erythromycin (5 μg/ml) and
tetracycline (1μg/ml). Escherichia coli strains were
grown in Luria-Bertani (LB) medium at 37°C with
ampicillin 100 μg/ml (or 200 μg/ml trimethoprim for
strain J53 [pR751]). Lactococcus lactis strain UKLc10
and its derivative strains were grown in M17 medium
(Oxoid) supplemented with 5 g/l glucose at 30°C.
Antibiotics were added as selection agents when appro-
priate: ampicillin 200μg/ml, erythromycin 5 μg/ml and
Table 1. Strains of bacteria used in this study.
Species Strain Plasmid Protein expressed Antibiotic selection* Reference
E. coli Rosetta 2(DE3) pLysS pGH165 St OmpA Amp, Cm This study
Rosetta 2(DE3) pLysS pGH201 St SseB Amp, Cm This study
Bt VPI-5482 DMSZ Collection
GH290 Tet This study
GH490 pGH090 Ery [21]
GH484 pGH182 St OmpA Ery This study
GH486 pGH183 St SseB Ery This study
GH474 pGH173 Hu. KGF-2 Ery This study
GH503 pGH184 IAV H5F Ery This study
S. enterica ser. Typhimurim SL1344 DMSZ collection
L. lactis UKLc10 [22]
*Amp = ampicillin; Cm = chloramphenicol; Tet = tetracycline; Ery = erythromycin
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chloramphenicol 10 μg/ml. The E. coli strain J53/R751
was supplemented with trimethoprim 200 μg/ml when
grown for 18 h. The E. coli strain GC10 and the L. lactis
strain UKLc10 were transformed by electroporation
using a Gene Pulser II (Bio-Rad). For constructs relat-
ing to pUK200, the host L. lactis strain UKLc10 was
used. Construction of other plasmids described below
was achieved using E. coli strain GC10 as the host.
Plasmids were mobilized from the E. coli into the Bt
following a triparental filter mating protocol [19] using
the helper strain J53/R751. All primers used are
detailed in Table 2.
Construction of a BT_3852 deletion mutant
A 1018 bp chromosomal DNA fragment upstream
from BT_3852 and including the first 18 nucleotides
of its 5ʹ-end region was amplified by PCR using the
primer pair f-5ʹompA_SpHI, r-5ʹompA_SalI. This pro-
duct was then cloned into the SpHI/SalI sites of the
E. coli-Bacteroides suicide shuttle vector pGH014 [20].
A 761 bp chromosomal DNA fragment downstream
from BT_3852, including the last 46 nucleotides of
the 3ʹ-end region, was amplified by PCR using the
primer pair f-3ʹompA_BamHI, r-3ʹompA_SacI and
was cloned into the BamHI/SacI sites of the pGH014-
based plasmid. The resulting plasmid containing the
ΔBT_3852::tetQ construct, was mobilized from E. coli
strain GC10 into Bt by triparental filter mating [19],
using E. coli HB101(pRK2013) as the helper strain.
Transconjugants were selected on BHI-haemin agar
containing gentamicin (200 mg/L) and tetracycline
(1 mg/L). Determination of susceptibility to either tet-
racycline or erythromycin was done to identify recom-
binants that were tetracycline resistant and
erythromycin susceptible after re-streaking transconju-
guant bacteria on LB-agar containing tetracycline or
both antibiotics. PCR analysis and sequencing were
used to confirm allelic exchange. A transconjugant,
GH290, containing the ΔBT_3852::tetQ construct
inserted into the Bt chromosome was selected for
further studies.
Generation of recombinant BT strains
BT Salmonella OmpA/SseB
The Bacteroides expression vector pGH090 [21] was first
digested with NdeI to remove this site by Klenow treat-
ment and to create a blunt-ended fragment that was then
religated. A sequence containing 90 bp of the BT_3852
gene 5ʹ end (encoding a major outer membrane protein,
OmpA) corresponding to the signal peptide sequence
(SpOmpA) of the protein obtained from the microbial
genome database (http://mbgd.genome.ad.jp/) was used
to design the complementary oligonucleotide pair
SPBTOmpA_fwd and SPBTOmpA_rev. Signal peptide
prediction was obtained by SignalP (http://www.cbs.dtu.
dk/services/SignalP/). After annealing of the oligonucleo-
tides the resulting double-strand DNA contained EcoRI
and SpHI 5ʹ overhangs at each end. This linker was cloned
into the EcoRI/SpHI sites of the NdeI deleted version of
pGH090, resulting in the pGH202 plasmid. The 1131 bp
Salmonella ompA (without signal peptide) and the 591 bp
sseB coding region were amplified by PCR from
S. enterica ser. Typhimurium SL 1334 genomic DNA
using the primer pairs OmpAST_fwd with
OmpAST_rev, and SseB_fwd with SseB_rev, respectively.
The resulting fragments were digested with NdeI and
EcoRI and cloned into NdeI/EcoRI-digested pGH202,
yielding plasmids pGH182 and pGH183, respectively.
The latter plasmid was then transformed into E. coli-
competent cells (GC10) by electroporation using a Gene
Pulser II (Bio-Rad). Successful cloning was confirmed by
sequencing. The plasmid was mobilized from E. coli to Bt
Table 2. Primer sequences used in this study.
Primer Sequence (5ʹ→ 3ʹ) a
f-5ʹompA_SphI ATCTGCATGCTTTCGAGGAAGAACCGATGGTTGC
r-5ʹompA_SalI ATACGTCGACAATATAGCGGACTGCAATCC
f-3ʹompA_BamHI ACTTGGATCCTTCTGAATCGTGTGGTATTGG
r-3ʹompA_SacI ACTAGAGCTCATCTGTAGAGAAGAAACGGG
SPBTOmpA_fwd CATGTTGCTGGCTTTTGCCGGCGTTGCGTCTGTCGCTTCTG
CGCAGCAAACCGTGACTGTAACTGAATACGAGGTTATTCATATGTGACG
SPBTOmpA_rev AATTCGTCACATATGAATAACCTCGTATTCAGTTACAGTCACGG
TTTGCTGCGCAGAAGCGACAGACGCAACGCCGGCAAAAGCCAGCAA
OmpAST_fwd TGACCATATGGCTCCGAAAGATAACACC
OmpAST_rev GTCAGAATTCTTAAGCCTGCGGCTGAGTTA
SseB_fwd TGACCATATGTCTTCAGGAAACATCTT
SseB_rev TGACGAATTCATGAGTACGTTTTCTGCG
XhoI_STOmpA_rev ATATCTCGAGGAAACTTAAGCCTGCGG
XhoI_SseB_rev ATATCTCGAGATGAGTACGTTTTCTGCG
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using a triparental mating procedure [19], together with
E. coli J53 (pR751); the correct structure of the Bt carrying
pGH182 (GH484) was confirmed by sequencing.
BT IAV
A 635bp synthetic gene construct encoding a synthetic
influenza (H5F; from IAV strain H5N1 [VN/04:A/
VietNam/1203/04]) pre-fusion headless HA mini-stem
N-terminally fused to the OmpA signal peptide of Bt was
created in silico and its codon usage was optimised for
expression in the same species. The resulting gene cassette
was obtained by gene synthesis and subsequently cloned
into the E. coli plasmid pEX-K168 (Eurofins). The cassette
contained BspHI and EcoRI restriction sites at its 5ʹ and 3ʹ
ends, respectively, allowing for the translational fusion of
the gene to the start codon in the Bacteroides expression
vector pGH090 [21]. The genewas excised frompEX-K168
using BspHI and EcoRI and ligated into the NcoI/EcoRI-
restricted pGH090 expression vector, resulting in pGH184.
Finally the sequence integrity of the cloned fragment was
confirmed by sequencing. The plasmidwasmobilized from
E. coli into Bt through a triparental mating procedure.
BT KGF-2
A 581bp synthetic gene construct encoding the human
fibroblast growth factor-10/keratinocyte growth factor-2
(KGF-2) N-terminally fused to the OmpA signal peptide
of Bt was created in silico and its codon usage was opti-
mised for expression in the same species. The resulting
gene cassette was obtained by gene synthesis and subse-
quently cloned into the E. coli plasmid pEX-A2 (Eurofins)
as described for the IAV constructs. The cassette contained
BspHI and EcoRI restriction sites at its 5ʹ and 3ʹ ends,
respectively, allowing for the translational fusion of the
gene to the start codon in the Bacteroides expression vector
pGH0902. The gene was excised from pEX-A2 using
Eco53KI and EcoRI and ligated into pUK200 [22], which
had been restricted with SmaI and EcoRI, resulting in
plasmid pUK200_KGF-2. Next the KGF-2 cassette was
excised from pUK200_KGF-2 through restriction with
BspHI and EcoRI and subsequently ligated into the NcoI/
EcoRI-restricted pGH090 expression vector, resulting in
pGH173. Finally the sequence integrity of the cloned frag-
ment was confirmed by sequencing. The plasmid was
mobilized from E. coli into Bt using a triparental mating
procedure.
Expression and purification of recombinant
StOmpA and StSseB
StOmpA was cloned into His6-tag expression vector
pET-15b (Novagen). Briefly, PCR fragments incorpor-
ating the coding sequences of ompA and sseB genes
were cloned into the NdeI/XhoI restriction sites of
pET-15b and the resulting plasmids pGH165 and
pGH201 transformed into Rosetta2 (DE3) pLysS cells
(Table 1). Cultures of the resulting strains were
induced at an of OD600 nm of 0.6 by adding 1mM
IPTG for 5 h after which time cells were harvested by
centrifugation (5500 g for 20 min). The pellet was
stored at −20°C for future use. StOmpA and StSseB
proteins were purified under native conditions using
protocols adapted from the QIAexpress Ni-NTA Fast
Start Handbook (Qiagen) with the amount of protein
recovered determined using the Bio-Rad Protein Assay.
OMV isolation and characterisation
OMVs were isolated following a method adapted from
Stentz et al. [20]. Briefly, cultures of Bt (500 mL) were
centrifuged at 5500 g for 45 min at 4°C and the super-
natants filtered through polyethersulfone (PES) mem-
branes (0.22 μm pore-size) (Sartorius) to remove debris
and cells. Supernatants were concentrated by ultrafil-
tration (100 kDa molecular weight cut-off, Vivaspin
50R, Sartorius), the retentate was rinsed once with
500 mL of PBS (pH 7.4) and concentrated to 1 mL
(approx. 700 µg/ml total protein). The final OMV
suspensions were filter sterilized (0.22 µm pore size).
The protein content of the final OMV suspensions was
determined using the Bio-Rad Protein Assay.
The distribution of heterologous proteins within Bt
OMVs was established in a Proteinase K accessibility/
protection assay [20]. Briefly, a suspension of 250 μg
(total protein) of OMVs in 0.1 M phosphate/1 mM
EDTA buffer (pH 7.0) was incubated for 1 h at 37°C in
the presence of 100 mg/L proteinase K (Sigma-Aldrich).
Proteinase K activity was stopped by addition of 1 mM
phenylmethanesulfonyl fluoride (PMSF) and samples
analysed by immunoblotting. The Sseb content of Bt
OMVs was determined by targeted proteomics done by
the Proteomics Facility, University Bristol, UK.
Nanoparticle analysis
Size distribution of vesicles was performed on 1ml of
OMV suspensions diluted 100 times with PBS. Videos
were generated using a Nanosight nanoparticle instru-
ment (NanoSight Ltd) to count the number of OMVs in
each sample. A 1-min AVI file was recorded and ana-
lysed using NTA (Version 2.3 Build 0011 RC, Nanosight)
software to calculate size distributions and vesicle con-
centrations using the following settings: calibration:
166 nm/pixel; blur: auto; detection threshold: 10, mini-
mum track length: auto, temperature: 21.9C, viscosity:
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0.96 cP. The accuracy of the measurement was confirmed
using 100 nm silver nanoparticles (Sigma-Aldrich).
Electron microscopy
The volume of OMV suspensions in PBS (1ml) was
adjusted to 8.9 ml with PBS and then concentrated by
ultracentrifugation; 150,000 g for 2 h at 4°C in a Ti70
rotor (Beckman Instruments). The vesicle containing
pellet was resuspended in 200 µl of PBS. The OMV
suspension was fixed for 1 h using 25% glutaraldehyde
then centrifuged at 13,000g for 10 min. The OMV
pellets were mixed 1:1 with molten 2% low gelling
temperature agarose (TypeVII, Sigma), which was soli-
dified by chilling and then cut into ~1 mm3 cubes. The
sample pieces were then further fixed in 2.5 % glutar-
aldehyde in 0.1 M PIPES buffer for 16 h at 4°C after
which time they were washed three times in 0.1 M
PIPES buffer and dehydrated through a series of etha-
nol solutions (30, 50, 70, 80, 90%, and 3 times in 10
0%) after which the ethanol was replaced with a 1:1
mix of 100% ethanol:LR White medium grade resin
and put on a rotator for 1 h. This was followed by
a 1:2 and then a 1:3 mix of 100% ethanol:LR White
resin mix and finally 100% resin, with at least 1 h
between each change. The resin was changed twice
more with fresh 100% resin with 8 h between changes.
The sample pieces were each transferred into BEEM
embedding capsules with fresh resin and polymerised
for 16 h at 60°C. Sections of ~90 nm thick were cut
using an ultramicrotome (Ultracut E, Reichert-Jung)
with a glass knife and collected on film/carbon coated
gold grids. A modified version of the Aurion
Immunogold labelling (IGL) protocol (http://www.aur
ion.nl/the_aurion_method/Post_embedding_conv) was
used with 1 h antibody incubations and detergent
(0.1% TWEEN). The primary anti-Bt OmpA antisera
was obtained by immunising rabbits with the peptide
GGPREDGSYKQRWDYMN (Cambrige Research
Biochemical), and was used at a dilution of 1/500.
The secondary anti-rabbit Ig (GAR-10, Agar
Scientific) was used at a dilution of 1/50. After anti-
body labelling, sections were stained with 2% uranyl
acetate for 40 min and imaged in a FEI Tecnai G2 20
Twin transmission electron microscope at 200 kV.
Immunoblotting
Bt cell and OMV extracts were obtained by sonication and
the supernatants added to SDS Page loading buffer
(NuPage) containing dithiothreitol (Invitrogen).
Approximately 7 μg of the total protein was loaded onto
12% precast Tris-Glycine gels (Novex) and separated by
electrophoresis at 180 volts for 40 min. The gel was then
transferred onto a polyvinylidene difluoride (PVDF)mem-
brane at 25 volts for 2 h in a solution containing Tris-
Glycine Transfer Buffer (Novex). The membrane was
blocked with 10% BSA in TBS-Tween (TBS [50 mM Tris-
HCl; 150mMNaCl; pH7.5]with 0.05%Tween) by shaking
for 30 min at 20°C. The blocking solution was then dis-
carded and the membrane incubated for 16–18 h at 4°C in
TBS-Tween with 5% BSA containing primary antibody
(anti-Salmonella OmpA [Antibody Research
Corporation], -KGF-2 [Peprotech] or -IAV or Anti-
polyHisitdine CloneHIS-1 (Sigma-Aldrich). After washing
withTBS-Tween,membraneswere incubated in 5%BSA in
TBS-Tween containing HRP-conjugated goat anti rabbit
IgG (1:1000 dilution, ThermoFisher) for 1 h at 20°C. After
3 washes with TBS-Tween, SuperSignal West Pico chemi-
luminescent Substrate (ThermoFisher) was used to detect
bound antibody.
Mammalian cell culture
The human colonic epithelial cell line Caco-2 (ECACC
86,010,202) was cultured at 37°C and 5% CO2 in
Dulbecco’s Modified Eagle Medium (DMEM) with
4.5 g/L glucose and L-glutamine (Lonza) supplemented
with 5% foetal bovine serum (FBS, Lonza).
Epithelial cell scratch assay
Caco-2 cells were grown in T25 flasks until they reached
90% confluency. Cells were digested using trypsin EDTA
(200 mg/L, 170,000 U Trypsin/L, Lonza) and seeded onto
8-well µ-slides (Ibidi). Cells were grown until they formed
a 90%confluentmonolayer and then serum-starved for 8 h.
A scratch was made on the monolayer using a sterile tip
and cells were washed with PBS to remove cell debris. The
remaining cells were incubated for 72 h in 1% FBSmedium
supplemented with heparin (300 µg/mL grade I-A,
>180USP units/ml; Sigma-Aldrich) in the presence of
PBS, naïve OMVs, KGF-2 OMVs or recombinant KGF-2
(500 ng/mL, PeproTech). Wound healing was monitored
by taking images immediately after scratching (time 0
control) and every 24 hours using an Invertoskop ID03
inverted microscope (Carl Zeiss) and a Sony Xperia Z5
compact digital camera (Sony). The measurements of the
recovered scratch area (pixel2) at each time point were
analysed using ImageJ software. The experiment was per-
formed in triplicate.
Animal experiments
All animal experiments were done using 6 to 8 week
old C57BL/6 male mice that were bred and maintained
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in animal facilities either at the University of East
Anglia (UK) or the University of Liverpool. Mice
were housed in individually ventilated cages and
exposed to a 12 h light/dark cycle with free access to
a standard laboratory chow diet. Animal experiments
were conducted in full accordance with the Animal
Scientific Procedures Act 1986 under UK Home
Office (HMO) approval and HMO project license 70/
8232 (UEA) and 70/8599 (UoL).
OMV vaccines and vaccination: To evaluate oral
Salmonella OMV vaccine formulations, groups of mice
(n = 5–6/group) were gavaged with either 100 μl contain-
ing approximately 70 µg of total protein and 1010 vesicles
of StOmpA-OMVs or naïve OMVs in PBS. Prior to each
immunization food was removed for approximately 4
h to decrease stomach acidity. Booster oral immunisa-
tions were given 1 and 2 months later. An additional
control group of animals were immunised with StOmpA-
OMVs via the intraperitoneal route. To assess intranasal
immunisation with Salmonella and influenza virus OMV
vaccine formulations, groups of mice (n = 5–10/group
mice were anaesthetized then intranasally dosed with
either StOmpA OMVs, StSseB OMVs, H5F OMVs,
naïve OMVs (~70 µg of total protein) or PBS and 14
and 21 days later received booster immunizations. For
infectious challenge with Salmonella, StOmpA-OMV
orally or intraperitoneally (IP) immunised mice were
orally administered 108 CFU of S. enterica ser.
Typhimurium SL1344 on day 70 and 5 days later the
bacterial load in different tissues was determined. For
infectious challenge with IAV, H5F-OMV immunised
mice were anaesthetised on day 28 with ketamine via
the intra-muscular route and inoculated intranasally
with 103 PFU A/PR/8/34 (PR8) H1N1 strain of IAV in
50 μl sterile PBS, which is equivalent to a 10-fold lethal
dose. Weights of each animal were recorded from the day
of challenge up until the end point at day 33 when the
mice were euthanised. At necropsy, blood, serum and
bronchoalveolar lavage fluid were taken for antibody
and cytokine analyses and lung tissue was used to deter-
mine virus titre. For in vivo OMV trafficking studies,
mice were intranasally administered with DiO-labelled
H5F-OMVs and 1 and 5 days later OMV acquisition
and uptake was determined using flow cytometry in: the
macrophage and dendritic cells of the BAL; nasal asso-
ciated lymphoid tissue (NALT); and cervical and med-
iastinal lymph nodes.
IAV quantification
Plaque assays were performed on homogenates of lung
tissue from PR8-infected mice as described previously
[23]. Briefly, viral samples from lungs were titrated in
a 10-fold serial dilution from 101 to 106 in DMEM
supplemented with TPCK-trypsin. Each dilution was
incubated with MDCK cells in individual wells of a 24
well plate for 1 hour at 37°C, 5% CO2. The media was
aspirated and replaced with overlay media containing
2.4% Avicel. Plates were incubated at 37°C, 5% CO2 for
72 hours. Avicel was aspirated, plates were washed and
cells were fixed in acetone:methanol (60:40) for 10 min.
Cells were allowed to air dry prior to staining with
crystal violet for 10 minutes, washed and air dried.
Plaques were counted and then multiplied by the dilu-
tion factor and the volume of virus plated to give viral
titre (PFU/ml).
Acute colitis
The dextran sulphate sodium (DSS) inducedmouse model
of acute colitis was used to test the therapeutic potential of
KGF-2-containing OMVs. Mice were divided into six
groups (n = 5/grp) and administered with either PBS,
naïve OMVs, KGF-2 OMVs, DSS + PBS, DSS + naïve
OMVs or, DSS + KGF-2 OMVs for 7 days. Experimental
colitis was induced in the appropriate treatment groups of
mice by administration of 2.5% w/v DSS (36,000–-
50,000 Da, MP Biomedicals, USA) in drinking water ad
libitum for 7 days. The other groups of mice received fresh
water alone throughout the duration of the experiment.
PBS and OMVs were administered by oral gavage (100 µL)
on days 1, 3 and 5 and on day 7 mice were euthanized.
Fresh faecal pellets were collected daily by placing indivi-
dual mice in an empty cage without bedding material for
5–15min.The extent of colitiswas evaluatedusing adisease
activity index (Table S1) comprising daily body weights,
stool consistency and rectal bleeding assessments. At
autopsy the colon was aseptically extracted and photo-
graphed, and the contents collected in sterile vials and
stored at −80°C. The colon length was measured, and
representative samples (0.5 cm length) were taken from
the distal region for histology. Histological samples were
fixed in 10% neutral buffered formalin and embedding in
paraffin. Tissue sections (5 μm) were prepared from each
block, stained with hematoxylin (Mayer’s hemalum,Merk)
and eosin (Y-solution 0.5% aqueous, Merck) (H&E), and
withAlcian blue (Sigma-Aldrich) andNuclear Red (Sigma-
Aldrich) to visualise goblet cells. Sections were observed
under a DMI 3000B microscope at 40X magnification
(Leica) and assessed in a blinded fashion. The histological
changes were scored (Table S2) and goblet cells were
enumerated using ImageJ software.
Antibody ELISA
ELISA plates were coated with target antigens (UV
inactivated IAV [PR8] virus or H5 (H5N1) (A/
Vietnam/1203/2004) Recombinant Protein (P5060, 2B
Scientific Ltd), Salmonella OmpA or SseB proteins) in
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0.1M NaHCO3 and incubated for 12–16 hours at 4°
C. Plates were washed three times with PBS that had
been supplemented with 0.05% Tween 20 (PT), and
then incubated with blocking solution (PBS with 2%
BSA) for 3 h at 20°C, and then washed six times with
PT. Fecal pellets were homogenized in phosphate-
buffered saline (pH, 7.2) with soybean trypsin inhibitor
(0.5 mg/mL; Sigma), phenylmethylsulfonyl fluoride
(0.25 mg/mL; Sigma), 0.05 M EDTA, and 0.05%
Tween 20 (Sigma). The fecal homogenates and bronch-
oalveolar lavage (BAL) and serum samples were diluted
in PBS with 1% BSA, 0.05% Tween (PBT) and added to
the plate wells and incubated for 12–16 h at 4°
C. Immune serum and BAL from PR8 IAV-infected
mice were used as reference samples for analysing anti-
IAV antibody responses in H5F-OMV-immunised ani-
mals. Plates were then washed six times with PT and
incubated with PBT containing either HRP-anti-mouse
IgG (1:1000, Thermo-Fisher) or HRP-anti-mouse IgA
(1:1000, Life Technologies) for 20 min at 20°C. Plates
were again washed six times with PT then incubated in
darkness with TMB High Sensitivity substrate solution
(BioLegend) for 30 min at 20°C. The reaction was
stopped by the addition of 2 N H2SO4 and the optical
density was measured at 450 nm using a TECAN infi-
nite f50 spectrophotometer (Männedorf, Switzerland).
Abcam’s IgA Mouse ELISA Kit was used to determine
total IgA in salivary glands and BAL
Flow cytometry
Approximately 1 × 106 tissue-derived cells were incu-
bated in PBS supplemented with 2% FCS (PBS-FCS)
for 15 min at 4°C prior to the addition of fluoro-
chrome-conjugated monoclonal antibodies specific for
CD11b (clone M1/70, eBioscience) CD11c (clone
N418, eBioscience), or CD103 (clone 2E7,
eBioscience) in PBS-FCS and incubated for 30 min at
4°C in darkness. Cells were then washed in PBS-FCS
and fixed in PBS supplemented with 4% paraformalde-
hyde for 15 min at 20 °C prior to analysis on
a MACSQuant Analyzer 10 (Miltenyi Biotech). Data
were analysed using FlowJo.
Immunohistology
From all mice, the entire, skinned heads were fixed in
10% buffered formalin for 48 h. Subsequently, approxi-
mately 2 mm slices were prepared by sagittal sections,
using a diamond saw (Exakt Band System 300 CL;
EXAKT Technologies Inc.), yielding a total of six sec-
tions from the tip of the nose to the foramen occipitale
magnum. Sections were gently decalcified for 7 days in
RDF Mild Decalcifier (CellPath Ltd) at room
temperature. Likewise, thoracic organs (lungs, lymph
nodes, heart and thymus) were removed en bloc, fixed
for 24 h in 10% buffered formalin and trimmed. Head
and organ specimens were then routinely paraffin wax
embedded. Consecutive sections (3–5 µm) were pre-
pared and were stained with haematoxylin eosin for
histological examination, or subjected to immunohis-
tological staining. Immunohistology (IH) was per-
formed using the horseradish peroxidase method as
previously described [24,25]. Primary antibodies used
were rat anti-mouse CD45R (clone B220, BD
Biosciences; B cells), rabbit anti-CD3 (clone SP7;
Bioscience; T cells) and rabbit anti-Iba-1 (Wako;
macrophages and dendritic cells).
Statistical analysis
Data were subjected to the D’Agostino & Pearson
omnibus normality test. One-way ANOVA followed
by a Tukey’s multiple comparison post hoc tests were
made using GraphPad Prism 5 software. Statistically
significant differences between two mean values were
established by a p-value < 0.05. Data are presented as
the mean ± standard deviation.
Results
Characteristics and physical properties of BT OMVs
Using electron microscopy we showed that OMVs
budded off from the outer membrane of Bt during its
growth cycle (Figure 1(a)) and could be recovered by
filtration and ultracentrifugation from early stationary
growth phase cultures (see Material and Methods). Bt
OMVs were identified by their characteristic double
membrane of their parental cells and by immunoreac-
tivity with anti-Bt OmpA antisera (Figure 1(b)). Bt
OMVs ranged in size from approximately 100 nm to
greater than 400 nm with a mean size of 237 nm
(Figure 1(c)). Bt OMVs are also highly stable with
minimal loss of luminal proteins (<10% of total protein
or heterologous protein) detected after exposure to an
elevated ambient temperature of 40 °C for up 30 days
(Figure 1(d)).
Heterologous bacterial, viral and human proteins
expressed in BT and incorporated into OMVs
To test whether the delivery of a wide range of hetero-
logous antigens into Bt OMVs was possible we com-
pared delivery of a number of selected candidate
vaccine antigens. These included antigens for the
important bacterial and viral pathogens S. enterica
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ser. Typhimurium enterica and IAV, respectively. For
a human protein we chose keratinocyte growth factor-2
(KGF-2). For S. enterica ser. Typhimurium we chose
the outer membrane protein, OmpA and the SPI-2
translocon subunit (SseB) because they elicit antibody
and T cell responses and confer some degree of pro-
tective immunity in mice, and because antibody
responses in humans correlate with immune protection
[26–34]. For IAV, the H-stalk protein H5 of the H5N1
VN/04:A/VietNam/1203/04 subtype was selected as it
confers robust protection against challenge by multiple
strains of IAV and can reduce lung viral titres by 3-fold
[35–37]. We also chose KGF-2 because it is essential
for epithelial cell proliferation and preserving the integ-
rity of the intestinal mucosa [37], and has therapeutic
potential for the treatment of inflammatory bowel dis-
ease [38].
Mini-genes encoding the selected bacterial, viral and
human proteins were cloned downstream of sequences
encoding the N-terminal signal peptide of the major
outer membrane protein OmpA (BT_3852), the pro-
ducts of which are contained within the lumen or outer
membrane of OMVs (Figure 2(a)). These constructs
were created in L. lactis (for KGF-2) or E. coli (for
Figure 1. Appearance, size, structure and stability of Bt OMVs. (a) Electron microscopy (EM) of Bt cells showing vesicles budding
from their surface before release into the milieu (lines in left panel), and EM image of OMVs extracted from cell culture supernatants
(right panel). (b) Immunodetection of naïve Bt OMVs using colloidal gold anti-rabbit Ig to detect binding of rabbit anti-Bt OmpA
antisera (right panel). Left panel shows absence of staining of OMVs produced by an OmpA deletion mutant of Bt. (c) Size
distribution of OMVs produced by Bt determined by nanoparticle tracking analysis. (d) Thermostability of OMVs at day 0 (OMV D0)
and after storage of OMV suspensions at 4°C or 40°C for 30 days as measured using immunoblotting to detect OmpA in extracts of
naïve OMVs (OMV) or OMVs of ompA deletion mutants (OMV-), and of neat (1) or ten-times concentrated (10) OMV storage buffer
(SB) (PBS was the storage buffer).
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OmpA, SseB and HF) hosts and then mobilised into Bt
via a triple filter mating protocol using a helper strain.
Immunoblotting of whole cell and OMV lysates of
recombinant Bt strains confirmed expression of
OmpA (Figure 2(b)) and KGF-2 proteins (Figure 2
(c)). The luminal versus outer membrane distribution
of these heterologous proteins in Bt OMVs was estab-
lished using a protease protection assay which showed
that Salmonella OmpA distribution was associated with
the outer membrane (Figure 2(b)) whereas KGF-2
(Figure 2(c)) was contained within the lumen of
OMVs. SseB expression was undetectable in OMV
preparations using immunoblotting, but was detectable
by liquid chromatography and mass spectrometry-
(LC-MS) based proteomics, which also established its
localization to the lumen of OMVs (Supplementary
Table S3).
BT OMVs have inherent adjuvanticity
Many conventional vaccines rely on the inclusion of
adjuvants to enhance their immunogenicity and to
reduce the number of doses and amount of antigen
(or pathogen component) required to elicit a protective
immune response, particularly in immunocompro-
mised individuals [2,39]. To formally evaluate the adju-
vant properties of Bt OMVs, mice were administered
a single dose of native OMVs in PBS via the intranasal
route and 5 days later head and thoracic organs were
removed en bloc and analysed by immunohistology for
the presence of organised lymphoid structures and
follicles indicative of an active immune response.
Large organised lymphoid follicles were present in
both the nasal cavity (nasal-associated lymphoid tissue
or NALT (Figure 3(a)) and the lungs (bronchus-
associated lymphoid tissue or BALT) (Figure 3(b))
which contained dendritic cells, T cells and large num-
bers of B cells. These structures were absent in mice
administered PBS alone (Figure 3(a,b)). Of note,
OMVs were also effective at eliciting the formation of
lymphoid clusters in mediastinal adipose tissue (fat-
associated lymphoid clusters or FALC) (Figure 3(c)).
Consistent with the immune response priming ability
of Bt OMVs, within 24 h of intranasal administration
of fluorescent labelled native OMVs it was possible to
detect their uptake in the NALT and draining cervical
Figure 2. Expression of heterologous proteins in Bt OMVs. (a) Schematic of cloning procedure for the export of proteins of interest
into the lumen or at the surface membrane of OMVs. The secretion peptide of Bt OmpA (SP BtompA) is indicated in yellow and
fused at the N-terminus of the gene of interest. (b and c) Determination of protein location after treatment with proteinase K (PK).
Immunoblotting of StOmpA (b) and KGF-2 (c) with and without pre-treatment of OMV suspensions with proteinase K. NT: not
treated; PK: + Proteinase K; B: PK buffer alone. (d) KGF-2 quantification within OMVs. Comparison of recombinant KGF-2 (1–100 ng)
with 10 µl of 1 ml OMV suspension (S).
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lymph nodes (CLN) (Supplementary Fig. S1). At day 5,
there was evidence of trafficking of OMVs to both the
cervical and mesenteric lymph nodes which was almost
exclusively mediated by CD11c+, CD11b+ CD103− den-
dritic cells (Supplementary Figure S1).
From a biosafety perspective, neither orally nor intran-
sally administered native OMVs or vaccine antigen for-
mulated OMVs had any adverse health effects with no
tissue pathology evident in treated animals at post mortem
(data not shown). Orally administered OMVs also had no
or a minor and/or transient effects on intestinal microbes
as determined from culturing faecal samples on selective
media (Supplementary Fig. S2).
Mucosal delivery of OMV vaccine formulations
We used preparations of OMVs expressing Salmonella
vaccine antigen (St-OmpA and St-SseB) to compare and
optimise the effectiveness of different formulations and
routes of administration for the generation of mucosal
and systemic antibody responses. St-OmpA and St-SseB
expressingOMVswere administered tomice via the oral or
nasal routes (Figure 4(a)) and also parenterally for compar-
ison. At the end of the study BAL and serum samples were
analysed by ELISA for antigen-specific IgA (mucosal) and
IgG (serum) antibodies, respectively. For St-OmpAOMVs
the intraperitoneal route of administration generated the
highest levels of antigen-specific serum IgG antibodies
compared with the oral or intranasal routes of delivery,
for which there were comparable, but only low levels, of St-
OmpA-specific IgG (Figure 4(b)). For St-SseB OMVs, the
intranasal route of administration generated significantly
higher levels of antigen-specific serum IgGantibodies com-
paredwith oral delivery andwere equivalent to the levels of
antigen-specific IgG seen after intraperitoneal immunisa-
tion (Figure 4(b)).
St-OmpA and St-SseB OMVs were equally effective at
elicting antigen specific IgA antibodies in the lower respira-
tory tract and BAL (Figure 4(c)). However, there was more
individual variation in the IgA levels and response to St-
OmpA OMVs compared with animals administered St-
SseB OMVs. Intranasally-administered St-OmpA and St-
SseB OMVs also increased global IgA antibody production
and secretion in both the salivary glands (Figure 4(d)) and
BAL (Figure 4(e)). Of note, naïve OMVs also increased
global IgA levels in these sites (Figure 4(d,e)), which is
consistent with the adjuvant properties of Bt OMVs and
their ability to activate the immune system in both of these
sites, and generate organised lymphoid follicles and tissues
containing large numbers of B cells (Figure 3).
Despite the induction of Salmonella antigen-specific
IgG antibodies, neither oral nor parenteral vaccination
with StOmpA-OMVs conferred signficiant levels of
protection to oral Salmonella infection as judged by
the pathogen burden (CFU) in intestinal and extra-
Figure 3. Intrinsic adjuvanticity of Bt OMVs. (a) Mice (n = 5)
were intranasally adminstered PBS alone native Bt OMVs (OMV)
in PBS and 5 days later heads and thoracic tissue was pro-
cessed for immunohistology to visualise immune cell activation
and formation of organised lymphoid tissue containing CD45R+
B cells (B220), CD3+ T cells (CD3) and macrophages/dendritic
cells (Iba-1) in the nasal associated lymphoid tissue (a) the lung
parenchyma (b) and mediastinal adipose tissues (c). Red arrows
define nasal-associated lympoid tissue (NALT), bronchus-
associated lymphoid tissue (BALT) and fat-associated lymphoid
tissue (FALC) in a, b and c respectively. NC: nasal cavity, NS:
nasal septum, P: hard palate.
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Figure 4. Bt OMV-elicitied systemic and mucosal antibody responses. (a) Mice (n = 5–6/grp) were administered Bt OMVs expressing the
SalmonellaOmpA or SseB proteins via the oral (OG), intranasal (IN) or intraperitoneal (IP) routes according to the dosing regimen described in
theMaterial and Methods section. Arrows indicate time of immunization. Naïve OMVs (nOMV) and PBS were administrated tomice (n = 5–6/
grp) as control groups. At autopsy, serum (b) and brochoalveolar lavage fluid (BAL) (c) were analysed for anti-OmpA and anti-SseB IgG and IgA
antibody titres, respectively, by ELISA. The boxplots indentify the mean and upper and lower quartile values for data sets obtained from
animals within each treatment group. Analysis of variance for multiple comparisons of means between independent samples (ANOVA) was
followed by a Tukey’s test. *P < 0.05; **P < 0.01; ***P < 0.001; ns,not significant. Total IgA levels were also determined in salivary gland tissue
homogenates (d) and in BAL (e) samples from each group of animals by ELISA using IgA standards as described in theMaterials andMethods
section.
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intestinal tissues at 5 days post infection
(Supplementary Fig. S3).
Intranasal OMV viral vaccine formulations protect
against pulmonary IAV infection
Based on the potent adjuvant effect of intranasally admi-
nistered OMVs (Figure 3) and higher levels of antigen
specific mucosal and systemic antigen specific antibodies
after intranasal immunisation with OMV based vaccines
(Figure 4), we used IAV vaccine formulated OMVs to
investigate further the possibility that intranasal immuni-
sation with OMV-based vaccines is a better option for
mucosal vaccination and conferring protection to infec-
tious challenge.
Serum anti-IAV IgG antibody levels were higher in
H5F-OMV immunised animals than the other groups
(Figure 5(a)). Animals immunized with naïve OMVs had
levels of BAL anti-IAV IgG antibodies significantly higher
than in non-immunized animals (Figure 5(b)). However, it
should be noted that levels of specific IgG in the OMV-
vaccinated groups were far lower than that seen with
a positive control serum from PR8-infected mice (Figure
5(b,c); black triangles). IAV specific IgA antibody levels
were significantly higher in the BAL samples from animals
immunised with H5F-OMVs compared with the other
groups (p = 0.004) (Figure 5(d)). Of note, the levels of anti-
PR8 (H1N1)-specific IgA seen in OMV-inoculated mice
were comparable to those seen in the positive control BAL
from homologous PR8-infected mice. Also, the levels of
H5 HA-specific IgA in BAL of the control PR8-infected
mice were not above control, demonstrating the lack of
cross-type specific HA IgA antibodies in PR8-infected
mice. Thus, vaccination with OMVs and H5F-OMVs
induced levels of antibodies, in particular IgA in the BAL
that were able to react with homologous H5 as well as
heterotypic H1HAmolecules. During infection the weight
of all infected animals declinedwith the greatest weight loss
seen in the control (PBS administered) animals that lost
almost 20% of their body weight (Figure 5(f)). Animals
immunised with H5F-OMVs displayed a more gradual
decline in weight loss after infection, as did those immu-
nized with naïve OMVs. Notably, the body weight of the
H5F-OMV-immunised animals stabilised with no further
decline between day 4 and day 5 post-infection; this is
indicative of a less severe infection from which they recov-
ered. This was confirmed by the lung viral titre data (Figure
5(g)); viral load in animals that had been immunised with
H5F-OMVswas significantly lower (p < 0.006) than that of
the other groups, reflecting an approximate 7 to 8-fold
lower level of virus.
KGF-2 containing omvs protect against acute
colitis
To determine whether Bt OMVs were suitable for
mucosal delivery of human therapeutic proteins, the
KGF-2 protein was expressed in Bt OMVs. This was
achieved by cloning a mini-gene containing the cod-
ing sequence of the mature human kgf-2 gene and the
Bt OmpA signal peptide in Bt (Bt-KGF-2).
Immunoblotting of lysates of OMVs harvested from
cultures of Bt-KGF-2 (KGF-2 OMVs) established that
they contained approximately 5 µg/ml of KGF-2
(Figure 2(d)) and that the protein was contained
within the lumen of the OMVs (Figure 2(c)). The
biological activity of KGF-2 OMVs was confirmed in
an epithelial cell wounding (scratch) assay in which
the addition of intact KGF-2 OMVs to the epithelial
cell cultures promoted epithelial cell proliferation and
accelerated wound closure (Supplementary Fig. S4).
KGF-2 OMVs were tested in the acute murine DSS
colitis model (Figure 6(a)), which is a well charac-
terised, simple and reproducible model of intestinal
inflammation that is independent of lymphocyte-
mediated responses and in which the clinical severity
can be quantified and new therapeutic agents evalu-
ated [40]. Since DSS primarily affects epithelial cells
and inhibits their proliferation [40] this model is well
suited to testing the therapeutic potential of KGF-2
OMVs. The dosing regimen was based in part on
pilot experiments assessing the tolerability of OMVs
(data not shown) and our previous studies using
a B. ovatus strain engineered to express human
KGF-2 in vivo that had a therapeutic effect in DSS-
colitis [41].
KGF-2 OMVs controlled colitis both clinically and
pathologically. Weight loss was significantly reduced in
animals receiving KGF-2 OMVs compared with non-
treated animals (p < 0.01) or animals that had been
administered naïve OMVs (p < 0.001) (Figure 6(b)).
KGF-2 OMVs also reduced the impact of DSS on colon
shrinkage and reduction in length (Figure 6(c,e)),
which is an independent measure of inflammation
[42]. Consistent with the therapeutic effect of KGF-2
OMVs, disease activity index scores were significantly
lower in KGF-2 OMV-treated animals compared with
the other treatment groups (Figure 6(d) and
Supplementary Tables 1 and 2). In addition, colon
shortening caused by DSS-treatment was abated by
KGF-2 OMV administration (Figure 6(e)).
Histopathology showed that KGF-2 OMV treatment
reduced epithelial damage and inflammatory infiltrate
compared with non-treated mice and mice that had
been administered naïve OMVs (Figure 7(a)). KGF-2
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Figure 5. Bt OMVs expressing IAV H5F protein confer a level of protection to virus infection in mice. (a) Mice were immunised
intranasally with H5F-OMVs in PBS; controls were administered intranasally with naïve OMVs or PBS alone (mock) at the indicated
time-points; after 28 days all were challenged intranasally with a 10-fold lethal dose of IAV strain A/PR/8/34 (PR8, H1N1). At
necropsy serum (b) and brochoalveolar lavage fluid (BAL) (c, d) were analysed for IAV IgG and IgA antibodies by ELISA using UV-
inactivated PR8 virus. BAL samples were also analysed for H5 HA specific IgA antibodies (e) using recombinant H5 HA as the target
antigen. Immune serum and BAL from PR8 IAV-infected mice (PR8) were used as reference samples. (f) The weight of individual
animals in each group was assessed daily. (g) Lung homogenates were assessed for viral load (PFU/g lung tissue) at necropsy.
Statisitical analysis was performed using one-way ANOVA with Tukey’s multiple comparison tests (panels b,c,d,e,g) or two-way
ANOVA with Bonferroni post-tests. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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OMVs also had a beneficial effect on mucin-producing
goblet cells. Compared with non-treated animals or
animals receiving naïve OMVs, there was a signficiant
increase in the number of mucin-containing goblet
cells in the colonic mucosa of KGF-OMV-treated ani-
mals (Figure 7(b)); the appearance and distribution of
goblet cells resembled that of the control animals
receiving water alone and no DSS (Figure 7(c)).
Discussion
In this study we have provided evidence for the suitability
of using OMVs from the major human gut commensal
bacterium, Bt, to deliver biologics to mucosal sites and
protect against infection and injury. The nanosize andnon-
replicative status of Bt OMVs together with their stability
and ability to interact with mucosal and systemic host cells
makes them ideally suited for drugdelivery.Moreover, they
possess innate adjuvant properties and the ability to acti-
vate immune cells and promote development of the orga-
nised mucosa-associated lymphoid follicles that are
required for generating effective immune responses. The
use of OMVs from prominent human commensal bacteria
that have established a mutualistic relationship with, and
are well tolerated by, their host is also desirable from
a safety perspective and for minimising or preventing
inappropriate host responses. This was evidenced by the
absence of any change in health status and no pathology in
Bt OMV-treated animals.
Figure 6. OMVs containing KGF-2 ameliorate DSS-induced colitis in mice. (a) Groups of mice were provided with drinking water with
or without 2.5% (w/v) DSS for 7 days. On days 1, 3 and 5 mice were orally gavaged with either PBS, naïve OMVs or OMVs containing
KGF-2. (b) Percent weight loss at day 7. (c) Colon length at day 7. (d) Disease Activity Index (DAI) at day 7. (e) Representative images
of colons. Data expressed as mean ± SD (n = 5). Statisitical analysis was performed using one-way ANOVA with Tukey’s multiple
comparison tests. Mice gavaged with PBS and receiving regular drinking water were considered as the reference group for statistical
analysis. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001.
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The Bt OMV technology platform is underpinned by
our ability to engineer Bacteroides species [21,43,44] to
express heterologous proteins that retain their biological
activity [41,45,46]; using specific protein secretion
sequences heterologous proteins can be directed to the
periplasmic space for export and incorporation into the
lumen or outer membrane of Bt-generated OMVs. It has
not been possible to absolutely define the minimum (or
optimal) level of expression of heterologous proteins
necessary to elicit an appropriate host response.
However, low levels of expression that are only detectable
by high resolution LC-MS-based proteomics (as for
Salmonella SseB) are sufficient to induce robust host
mucosal and systemic antibody responses. For this reason
there was no apparent correlation between the levels of
expression of different proteins within or at the surface of
OMVs, and their ability to elicit a host response.
Determining the quantity of biologically active (KGF-2)
protein in OMV fomulations was made difficult by their
ability to resist disruption. OMV cargo does, however,
become accessible after uptake by host cells and in parti-
cular, antigen presenting macrophages and dendritic cells
as shown here and previously by others [8], which is most
likely as a result of anOMV-intracellularmembrane fusion
event [12].
To date, the majority of OMV applications have
focused on vaccine development [18] as they offer sig-
nificant advantages over conventional vaccines; they are
non-replicating, provide needle-free delivery, target
mucosal sites, have an established safety record, can elicit
Figure 7. OMVs containing KGF-2 protect and restore goblet cells in mice with DSS-induced colitis. (a) Histological score of colon tissue as
determined bymicroscopy of H&E stained sections obtained at necropsy. (b) Number of Alcian Blue stained goblet cells per mm2 of epithelial
area. (c) Microscope images of goblet cell distribution in representative colon sections stained with Alcian Blue. Data expressed as mean ± SD
(n = 5). Statisitical analysis was performed using one-way ANOVA with Tukey’s multiple comparison tests. *P < 0.05.
JOURNAL OF EXTRACELLULAR VESICLES 15
innate and antigen-specific adaptive immune responses,
possess self-adjuvant properties (i.e. microbe-associated
molecular pattern molecules [MAMPs] such as LPS), and
are relatively cheap and straightforward to produce. The
limitations of current non-commensal and pathogen-
derived OMV vaccines are the potential for unintended
toxicity due to associated toxins, low expression levels of
protective antigens, variable efficacy depending on source
and formulation, the need for exogenous adjuvants, and
the problem of incomplete protection due to strain varia-
tion. The work we describe here demonstrates that these
limitations can, to a large extent, be overcome by using
bioengineered Bt OMVs. The intranasal route of admin-
istration was superior to oral administration in terms of
elicting high levels of Salmonella vaccine antigen-specific
mucosal IgA and systemic IgG. This difference is most
likely a reflection of anatomical differences and the ease
of access to host immune inductive sites and effectiveness
of aquisition by mucosa-associated antigen presenting-
cells that occurs in the upper respiratory tract compared
with the lower GI-tract. With smaller distances to travel
in the less harsh environment of the lungs, OMVs are
more readily accessible to host cells; within 24 h of intra-
nasal administration Bt OMVs were acquired by CD103−
CD11b+ dendritic cells in the mucosa of the upper and
lower respiratory tract, with some trafficking to draining
lymph nodes. Importantly, this CD103− CD11b+ popula-
tion of tissue DC are known to traffic antigen to lymph
nodes and initiate T cell responses [47].
The failure to demonstrate protection against infectious
challenge in animals immunised with Salmonella OMV
vaccine formulations may be as a consequence of various
factors including sub-optimal expression of appropriate
quantities of immunogenic St OmpA antigen in Bt
OMVs and/or the generation of insufficient levels of func-
tional, pathogen-neutralising, antibodies. Although St
OmpA was previously identified as a potential cross-
species vaccine candidate [48] our findings are in line
with those of Okamura and colleagues [49] who found
no protection in chickens parenterally immunised with St
OmpA. However, the universal adjuvant properties of Bt
OMVs suggests they may still be of value in Salmonella
vaccine formulations as an adjuvant analogous to menin-
gococcal OMVs that provide potent adjuvanticity to
N. meningitidis recombinant protein-based vaccines
[50,51].
Weobtainedmore compelling evidence for the potential
of Bt OMV-based vaccines in the IAV H5F-OMV system
which, after intranasal administration, conferred
a significant level of heterotypic protection against an
unrelated subtype of IAV. There are numerous strains of
IAV and the virus evolves rapidly. This presents a challenge
to generating a “universal vaccine” that will protect against
multiple IAV strains. Most IAV vaccines do not afford
protection against heterologous strains of virus. Recent
work has shown that while the globular head of the IAV
HA molecule is highly variable and does not generate
cross-protective immunity, the stem/stalk is more con-
served and will generate cross-protective antibodies [52].
Naïve OMVs had a positive impact on the generation of
mucosal virus-specific IgA antibodies and also reduced
lung viral titres. This is most likely a reflection of their
potent adjuvant properties and the activation of innate
and adaptive immune responses, including raised total
IgA antibody levels in the upper and lower respiratory
tract which would strengthen front line protection against
IAV infection [53]. At 5 days post challenge with the
heterologous PR8 (H1N1) virus, the mean weight of H5F-
OMV-immunized animals stabilized which is indicative of
recovery from virus infection; which was supported by the
fact that H5F-OMV immunized animals had a 7–8-fold
lower lung viral titre compared with non-vaccinated ani-
mals or animals immunized with naïve OMVs. Future
refinements to the study protocol should provide a clearer
picture of the efficacy of OMV-H5F vaccines in preventing
IAV infection by both homotypic andheterotypic strains of
influenza virus. As our studywas not an end point studywe
cannot directly compare the level of protection against
infection conferred by OMV-H5F vaccines with similiar
studies trialingOMV-based vaccines; these include those of
Watkins and colleagues [54] who developed E. coli OMV-
IAV vaccines and achieved 100% protection in a murine
lethal infectious challenge model. Collectively, our data
provides the rationale and justification for continuing the
development and refinement of OMV technology to
improve and optimse their vaccine capabilities and
performance.
Our findings using KGF-2-containing OMVs to ame-
liorate experimental colitis demonstrates the potential for
a broader portfolio of applications and, in particular, for
the mucosal delivery of therapeutic proteins for the treat-
ment of non-infectious, autoimmune-driven pathologies.
The benefit of this form of drug delivery is exemplified by
comparing the doses required to improve colonic pathol-
ogy using OMV technology and a standard approach. The
dose of KGF-2 OMVs (approximately 0.5 µg) used to
achieve a significant reduction in colonic histopathology
is 1–2 orders of magnitude lower than that required in
daily injections (20–100 µg for 7 days) to achieve a compar-
able reduction in colonic pathology [55,56]. Also, the
ability to deliver the protein directly to the target tissue
using orally administered OMVs reduces the risk of side
effects associated with systemic delivery.
In summary, our data adds to the growing number
of new approaches being developed to express hetero-
logous proteins in bacterial microvesicles [18] for
16 A. L. CARVALHO ET AL.
a variety of applications. Our work provides evidence
for the utility and effectiveness of human commensal
bacteria as a source of bioengineered OMVs for the
mucosal delivery of different biologics.
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